In the News | Charles River
   
 
 
   
   

Online Extra: Preclinical Perspectives
Providers look to a brighter future
Contract Pharma
June 2012

Earlier in the drug development process, providers are finally seeing an uptick in sponsor demand for specialized services, after paring away at excess capacity and trying to right-size preclinical operations.  

Read what Nancy Gillett, corporate executive vice president and chief scientific officer at Charles River Laboratories, and other experts have commented on keeping up with this increased demand for services such as biomarkers, biosimilars, orphan drugs, as well as certain therapeutic areas. 

Click here to read the full article from Contract Pharma.

   
Discover the full range of Charles River Products and Services
The Source

For more information, contact us at:

1.877.CRIVER.1 (1.877.274.8371)
askcharlesriver@crl.com

view all

News & Events

view all
Jun 13 - Neurological Biomarkers in Efficac...
Jun 06 - GLP-Compliant ELISpot and FluoroSp...
Jun 24-Jun 26 - London, UK - Skin Forum 2013
Jun 21-Jun 25 - Chicago, IL - American Diabetes Association’s 73rd Scientific Sessions
Sep 09-Sep 11 - Carlsbad, CA - 19th Annual Biotechnology-Derived Therapeutics Perspecti...
Jun 28-Jun 28 - Frankfurt, Germany - Seminar: Health Monitoring of Laboratory Animals

Charles River Laboratories, Inc.